SK bioscience Launches Global Trial for Universal Sarbecovirus Vaccine

SK bioscience has officially initiated a global Phase 1/2 clinical trial for its vaccine candidate, GBP511, targeting the sarbecovirus subgenus. This announcement was made on January 29, 2026, and marks a significant step in the development of a vaccine designed to offer broad protection against coronaviruses, including SARS-CoV-2 and potential future variants. The trial will take place in Australia, involving approximately 368 adults aged 18 and older.

The GBP511 vaccine aims to induce comprehensive immune responses across the entire sarbecovirus family. This includes not only currently circulating variants but also SARS-like coronaviruses that may emerge from animal populations. During the Phase 1 portion of the trial, participants will receive two doses of the vaccine, spaced 28 days apart, across varying dosage levels. The trial will assess safety, tolerability, and immunogenicity, comparing GBP511 to the existing Comirnaty vaccine.

Dr. Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI), emphasized the pressing need for broadly protective vaccines, noting, “COVID-19 exposed the devastating price of confronting a deadly new virus without a vaccine.” He expressed optimism that vaccines like GBP511 could transform pandemic preparedness.

The Phase 2 trial is set to follow, contingent on the results from Phase 1. This stage will further analyze the vaccine’s immunogenicity and safety in both adult and elderly populations. Additionally, the study will evaluate cross-reactive immune responses against various strains of sarbecoviruses, reinforcing the vaccine’s potential as a universal solution.

GBP511 builds on the success of SKYCovione, which became Korea’s first domestically developed COVID-19 vaccine to receive commercialization approval. Utilizing a computer-designed antigen platform, GBP511 combines SK bioscience’s recombinant protein technology with advanced nanoparticle design technology developed by the Institute for Protein Design (IPD) at the University of Washington School of Medicine. SKYCovione has demonstrated a robust immunogenicity profile and a favorable safety record in global trials, which served as the foundation for its regulatory approvals.

The urgency for a universal coronavirus vaccine is underscored by CEPI, which has identified the sarbecovirus family as a “prototype pathogen.” This classification reflects the likelihood of future pandemics stemming from this viral group. CEPI has consistently advocated for a shift away from variant-specific approaches, emphasizing the necessity for vaccines that can deliver broad protection against emerging coronaviruses.

The global market for COVID-19 vaccines is projected to undergo a significant transition. According to market research firm Coherent Market Insights, the market is estimated to reach approximately USD 50.6 billion in 2025. It is expected to grow at a compound annual growth rate of 7.4% from 2025 to 2032, ultimately reaching around USD 83.4 billion by 2032. This sustained growth will likely be driven by next-generation technologies, including universal vaccines.

Jaeyong Ahn, CEO of SK bioscience, remarked on the importance of developing a universal sarbecovirus vaccine, stating, “This critical challenge must be addressed to prepare for the next pandemic.” He expressed confidence that the initiation of the GBP511 trial would accelerate vaccine development and position the company as a leader in the global vaccine market.

In addition to GBP511, SK bioscience is advancing various projects, including a 21-valent pneumococcal conjugate vaccine and an avian influenza vaccine. The company’s strategy focuses on expanding its vaccine portfolio to enhance preparedness for future infectious disease threats.

As the world navigates the complexities of vaccine development in the wake of the COVID-19 pandemic, SK bioscience’s efforts reflect an important commitment to global health and security. The progression of GBP511 into clinical trials highlights South Korea’s leadership in innovative vaccine solutions, aiming for a safer future for all.